Clinical trials: Psychedelic Experiences, active
Psychedelic Experiences, Neuroimaging
Neural and Physiological Correlates of Psychedelic Sub-states
The main purpose of this study is to gain a better understanding of the distinct mental states and physical reactions that can arise during a psychedelic experience.
- Conditions
- Psychedelic Experiences, Neuroimaging, Healthy Volunteers
- Trial name
- i2 (NCT05698511)
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Robin Carhart-Harris, PhD, MA
Alcohol Use Disorder (AUD), PTSD
PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for…
- Trial name
- Psi-PS (NCT06853912)
- Testing
- Psilocybin 25 mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Nathan Brashares Sackett
Depression - Major Depressive Disorder, Anhedonia
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
The goal of this clinical trial is to systematically categorize potential prohedonic effects of psilocybin in patients with anhedonia in depression. The main questions it aims to answer are: Primary Objectives 1.
- Trial name
- NCT07490353
- Testing
- Psilocybin (Usona Institute), Risperidone 1 MG, MRI
- Where
- Austria
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Obsessive - Compulsive Disorder
Psilocybin for Treatment of OCD-2
Previous research indicates that psilocybin, a drug that changes activity in brain areas believed to be involved in obsessive-compulsive disorder (OCD), might improve treatment for, and improve lives of, people diagnosed with…
- Trial name
- NCT06992999
- Testing
- Low Dose Psilocybin, High Dose Psilocybin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Francisco A Moreno
Healthy Adult Participants
Mystical Experiences Without Psychedelics and How Integration Improves Well-Being in Adults
The goal of this clinical trial is to evaluate whether a guided, non-drug spiritual intervention can facilitate mystical-type experiences and improve well-being in Christian adults.
- Trial name
- NCT07584070
- Testing
- Guided Invocation for Mystical Experience
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Baylor University
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Major Depressive Disorder, Psychedelic Experiences
Antidepressant Response of DMT Masked With Propofol
The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic…
- Trial name
- DMT4D (NCT06927076)
- Testing
- N,N-Dimethyltryptamine, Propofol, no sedation
- Where
- Switzerland
- Volunteers
- 112 people
- Sponsor
- University Hospital, Basel, Switzerland
Healthy, Psychedelic Experiences
The ENHANCE Study: taVNS and Psilocybin
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance…
- Conditions
- Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
- Trial name
- ENHANCE (NCT05866471)
- Testing
- Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Asperger's Disorder, Asperger Disorder
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum SI/SGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.
Investigating the Importance of the Subjective Psychedelic Experience
Subjective Experience Following Psilocybin
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes.
- Trial name
- SEP-1 (NCT06768944)
- Testing
- Psilocybin high-dose, Psilocybin low-dose, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Alcohol Use Disorder
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Twenty participants, age 18 or older, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for moderate to severe Alcohol Use Disorder will be randomized to open-label psilocybin (25 mg) therapy with…
- Trial name
- NCT04410913
- Testing
- Psilocybin plus Visual Healing Set and Setting, Psilocybin plus Standard Set and Setting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Keith Heinzerling
Well-Being, Psychological, Psychedelic Experiences
Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study
This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why.
- Trial name
- NCT07360301
- Testing
- Psilocybin, Clonidine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison